Other benefits of incretins were demonstrated in a retrospective cohort study, n = 1,651,452, mean age 59.8 ± 15.1 years, whose participants had no prior diagnosis of obesity‐associated cancers (OACs), had T2DM, and were prescribed GLP‐1 s, insulin, or metformin. This evidence concerns the gene INS and obesity disorder.